Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. (Record no. 23037007)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01887 a2200529 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250516165315.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201405s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2324-8645 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1089/humc.2012.240 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Spanggaard, Iben |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20140501 |
| 245 00 - TITLE STATEMENT | |
| Title | Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Human gene therapy. Clinical development |
| Date of publication, distribution, etc. | Sep 2013 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 99-107 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | ADAM Proteins |
| General subdivision | chemistry |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Angiogenesis Inhibitors |
| General subdivision | chemistry |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Electroporation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Genetic Therapy |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Melanoma |
| General subdivision | therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Membrane Proteins |
| General subdivision | chemistry |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Plasmids |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Protein Structure, Tertiary |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | RNA, Messenger |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Skin Neoplasms |
| General subdivision | therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Transfection |
| General subdivision | methods |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Snoj, Marko |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cavalcanti, Andrea |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bouquet, Céline |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sersa, Gregor |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Robert, Caroline |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cemazar, Maja |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dam, Elisabeth |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vasseur, Bérangère |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Attali, Pierre |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mir, Lluis M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gehl, Julie |
| 773 0# - HOST ITEM ENTRY | |
| Title | Human gene therapy. Clinical development |
| Related parts | vol. 24 |
| -- | no. 3 |
| -- | p. 99-107 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1089/humc.2012.240">https://doi.org/10.1089/humc.2012.240</a> |
| Public note | Available from publisher's website |
No items available.